Targets › VEGFR
7 programs from 7 companies in 7 trials: 7 Phase 2; Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: the race on VEGFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangxi Provincial Cancer Hospital | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT) | VEGFR, FGFR, RET, KIT | Phase 2 | Esophageal Squamous Cell Carcinoma | Nov 2026 |
| University of Utah | XL092 (Zanzalintinib) Multi-target kinase inhibitor targeting FGFR, VEGFR, and KIT | FGFR, VEGFR, KIT | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Sun Yat-sen University | Anlotinib Hydrochloride Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET | VEGFR, PDGFRA, PDGFRB, FLT1, KIT | Phase 2 | Glioblastoma | Dec 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR inhibitor) | VEGFR, FGFR, PDGFR | Phase 2 | Sarcoma,Soft Tissue | Dec 2027 |
| Eye & ENT Hospital of Fudan University | Anlotinib Hydrochloride Multi-target tyrosine kinase inhibitor | VEGFR, FGFR, RET, KIT | Phase 2 | Adenoid Cystic Carcinoma | Jun 2028 |
| Yu Wang | Donafenib Multikinase inhibitor targeting BRAF, VEGFR, and FLT3 | BRAF, VEGFR, FLT3 | Phase 2 | Thyroid Cancer | – |
| West China Hospital | Donafenib Multi-targeted tyrosine kinase inhibitor targeting RAF, VEGFR, and FLT3 | RAF, VEGFR, FLT3 | Phase 2 | Locally Advanced Thyroid Gland Carcinoma | – |
Glioblastoma (1) Thyroid Cancer (1) Esophageal Squamous Cell Carcinoma (1) Locally Advanced Thyroid Gland Carcinoma (1) Metastatic Castration-resistant Prostate Cancer (1) Adenoid Cystic Carcinoma (1) Sarcoma,Soft Tissue (1)
small molecule (6), antibody (1)
Sun Yat-sen University (1) Yu Wang (1) Jiangxi Provincial Cancer Hospital (1) West China Hospital (1) University of Utah (1) Eye & ENT Hospital of Fudan University (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
KIT (4) FGFR (4) FLT3 (2) RET (2) PDGFRA (1) PDGFRB (1) FLT1 (1) BRAF (1) RAF (1) PDGFR (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.